Official account of The University of Texas MD Anderson Cancer Center. Our mission is to #EndCancer through patient care, research, education & prevention.
Joined February 2008
- Tweets 44,882
- Following 4,183
- Followers 142,280
- Likes 40,435
9,611 Photos and videos
“Our new platform overcomes the limitations of current viral-based gene therapies, allowing for the delivery of full-length mRNA," says our Dr. Betty Kim on new research.
Read more: spr.ly/6010B8fqzC @BettyKimLab
#EndCancer
1
8
15
1,263
Jun 12
Results from the Phase 1/2 SAVE clinical trial found an all-oral revumenib-based combination therapy showed high response rates in patients with acute myeloid leukemia and specific genetic alterations: spr.ly/6016B8fUFG @GhayasIssa #EndCancer
1
5
17
1,643
UT MD Anderson retweeted
Did you hear?
@UTMDAnderson @NatureCancer @NatureRevCancer & @NatRevDrugDisc have partnered to bring together experts changing the landscape of cancer therapeutics. Secure your place today and hear about the next generation of treatments and technologies. go.nature.com/4dQh87x
1
4
10
1,464
Jun 11
Options for both first and second lines of treatment for lung cancer have flourished in recent years.
Dr. Carl Gay shares why there are reasons for optimism: spr.ly/6010B8F15o @WebMD #EndCancer
1
1
12
1,722
Jun 10
UT MD Anderson has joined a consortium dedicated to accelerating the elimination of cervical cancer worldwide.
This collaboration with the Elimination Partnership in Cervical Cancer expands our global oncology efforts, further advancing our commitment to #EndCancer. @kmschmeler spr.ly/6019B8NEkU
ALT A group of people standing together and smiling.
4
28
2,758
Jun 9
Researchers at UT MD Anderson are studying vibration plate technology, with the goal of protecting bone health in cancer patients.
Dr. Gabriel Pagnotti spoke to @NPR and says the benefits may extend to muscle as well: spr.ly/6015B8LnIP
1
2
17
1,586
Jun 8
Congratulations to UT MD Anderson president @ppisters on being named by @modrnhealthcr as one of the most influential healthcare executives for 2026.
More about the honor and Dr. Pisters' leadership: spr.ly/6015B8IqCS #EndCancer
ALT Graphic reads, \"Modern Healthcare's 50 most influential healthcare executives for 2026. Peter WT Pisters, M.D., President, UT MD Anderson.\"
1
5
46
3,532
Jun 7
Survivorship means something different for everyone.
This National Cancer Survivors Day, we honor every patient, family, friend and caregiver whose life is touched by cancer. Every story. Every step forward. #EndCancer
ALT Purple graphic that reads Every survivor has a story.
4
5
29
2,066
Jun 6
Researchers at UT MD Anderson have discovered a molecular pathway that drives certain cells to become abnormally active, resulting in disturbed blood flow and high-risk lesions that can lead to blood clots that cause heart attacks or strokes: spr.ly/6015B8qlAL #EndCancer
1
9
34
2,717
Jun 5
In this Cancerwise podcast episode, Hannah Kahn talks about her experience with a brain tumor.
She and @wendyegriffith also discuss fertility planning, hair loss, and the importance of staying connected with other survivors. Listen here: spr.ly/6013B8tGB9 #EndCancer
1
13
1,598
Jun 5
Immunocompromised cancer patients are disproportionately affected by invasive fungal pneumonias.
New findings could offer clinical strategies for treating these patients: spr.ly/6019B8UfnZ #EndCancer
1
6
23
1,820
Jun 4
Registration is open for two palliative medicine education events in September 2026.
Healthcare professionals will be equipped with essential skills to deliver compassionate, high-quality palliative and end-of-life care: spr.ly/6012B8mq0g #EndCancer
ALT Graphic reads, \"Palliative medicine - Two Virtual Education Events. September 15-17, 2026. Updates and hospice and palliative medicine and intensive physician board review course. September 18-19, 2026. 29th supportive and palliative clinical care and research symposium.\"
3
15
1,249
Jun 3
The construction of our new Sugar Land location is now halfway complete!
The new, larger campus will house many clinical services, including a new ambulatory surgery center and expanded modalities for diagnostic imaging, radiation oncology, and outpatient procedural services. #EndCancer
ALT Photo of a flag hanging from a crane.
ALT Photo of people standing in front of a construction site.
3
35
2,248
Jun 2
That's a wrap on #ASCO26.
This year, UT MD Anderson shared nearly 130 abstracts, including 34 podium presentations, advancing research and bringing new insights to cancer care. Thank you to everyone who connected with us at our booth, attended presentations and joined the conversation throughout the meeting.
@ASCO #EndCancer
ALT UT MD Anderson booth
ALT UT MD Anderson faculty at the booth.
ALT UT MD Anderson team after Dr. Giordano's award presentation.
ALT Dr. Scott Kopetz presenting.
9
48
2,295
Jun 2
Dr. Tim Yap, chairing a session at #ASCO26 on expanding synthetic lethality strategies beyond PARP, said that Werner (WRN) inhibitors are a promising approach for targeting microsatellite instability (MSI) cancers that are insensitive to standard-of-care therapy. #EndCancer
ALT Dr. Tim Yap
ALT Title slide
ALT Slide explaining WRN inhibitors
6
30
4,987
Jun 2
Promising efficacy compared to historical benchmarks supports the study of menin inhibition for patients with AML as post-stem cell transplantation maintenance, Dr. Hannah Goulart presented at #ASCO26. @HannahGoulart #EndCancer
ALT Dr. Hannah Goulart and one of her slides
7
21
1,559
Jun 2
The triplet combination of quizartinib, decitabine and venetoclax improved overall survival in older patients with newly diagnosed FLT3-ITD AML, Dr. Musa Yilmaz shared at #ASCO26. Learn more: bit.ly/4dKuq5v @MusaYilmazMD #EndCancer
ALT Dr. Musa Yilmaz
ALT Introductory title slide
ALT Key takeaways slide
1
10
35
2,824
Jun 2
At #ASCO26, Dr. Jennifer Marvin-Peek presented results from a Phase 1b/2 trial for patients with IDH1-mutated acute myeloid leukemia. The study looked at a novel triplet therapy of azacitidine, venetoclax and ivosidenib, which demonstrated high MRD-negative response rates and durable remissions. Learn more: bit.ly/4dKuq5v @JenMarvinPeek #EndCancer
ALT Dr. Jennifer Marvin-Peek and one of her slides
1
13
48
3,100
Jun 2
The combination of tagraxofusp, hyper-CVAD and venetoclax demonstrates promising safety and high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr. Naveen Pemmaraju presented these results at #ASCO26. @doctorpemm #EndCancer
ALT Dr. Naveen Pemmaraju
7
22
2,089